As LIN28 and FGFR1 are strongly related to the progression and prognosis of lung adenocarcinoma patients, and resistance to cisplatin is a major obstacle for the success of NSCLC therapy,44 we selected the adenocarcinoma cell line A549 and the cisplatin‐resistant cell line A549R to further validate the inhibitory effects of C1632 on LIN28 and FGFR1. Here, FGFR1 is linked to non-small cell lung carcinoma.